Journal articleCancer Discov2020
Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
- Journal
- Cancer Discov
- Published
- 24 October 2019
- Citations
- 214
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 14
- Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer F30CA243253↗
- Defining the Role and Mechanism of Pak1 in Supporting Pancreatic Cancer F31CA180628↗
- K-Ras mutant-specific vulnerabilities for novel pancreatic cancer therapies F32CA200313↗
- Targeting CDK4/6 for pancreatic cancer treatment F32CA221005↗
- Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer K08CA218420↗
- Project 3: Mechanisms and therapeutic targeting of NRAS in melanoma P01CA203657↗
- Immunology Research Program P30CA016086↗
- Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma P50CA127003↗
- Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
- Biological Activity of Ras Oncogenes R01CA042978↗
- Targeting undruggable RAS for cancer treatment R35CA232113↗
- Identification of synthetic lethal interactors in pancreatic cancer U01CA199235↗
- Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens U01CA224146↗
- Preclinical drug development in pancreatic cancer ZIABC011267↗